Win or Lose at Biopharma Launch: Lessons from Six Landmark Launch Cases

This study synthesizes lessons from six landmark launch cases through structured secondary research and case analysis. Drawing on regulatory filings, company announcements, payer and formulary data, analyst reports, and commercial performance data, the research examines the commercial, access, pricing, and positioning decisions that shaped outcomes for Casgevy and Lyfgenia, Zolgensma, Leqembi, Dupixent, Aimovig, and Enhertu. The findings translate those lessons into practical frameworks that launch leaders can apply to upcoming products across therapeutic areas.

Key Questions This Study Answers:

• What determined the commercial outcome of the Casgevy versus Lyfgenia simultaneous gene therapy launch?
• How did Zolgensma create payer confidence for a $2.125 million therapy before and at launch?
• Why does Leqembi reach under 1% of eligible patients despite full FDA approval and Medicare coverage?
• What made Dupixent's patient support and access infrastructure a durable competitive advantage at scale?
• What can Aimovig's pre-launch disease awareness campaign and Enhertu's patient population reclassification teach upcoming launches?

• Casgevy vs. Lyfgenia: Label Quality, Pricing, and Payer Access in Simultaneous Gene Therapy Launches
• Zolgensma: Inventing the Payer Model for a $2.125 Million Therapy
• Leqembi: Navigating Medicare Coverage and the 20-Month Referral Funnel in Alzheimer's Disease
• Dupixent: Building Patient Support and Access Infrastructure for Multi-Indication Growth
• Aimovig: Engineering Demand in a Stigmatized Market Before the First Prescription
• Enhertu: Redefining a Patient Population Through Clinical Evidence

• Casgevy and Lyfgenia list price, sales trajectory, and payer access model comparison
• Zolgensma outcomes-based contracting timeline and payer adoption milestones from approval to national coverage
• Leqembi patient reach as a percentage of the estimated eligible Alzheimer's population
• Dupixent revenue trajectory and patient support program design across indications
• Aimovig pre-launch market research scope and CGRP category education investment rationale
• Enhertu patient population reclassification scale and clinical data performance benchmarks

• Access Infrastructure and Label Quality Compound - For Better or Worse: The Casgevy versus Lyfgenia outcome illustrates how compounding disadvantages -- a Boxed Warning, a 41% price premium with no clinical superiority, and late Medicaid access -- can render a launch commercially unrecoverable. A label advantage alone is not sufficient: Leqembi, despite receiving full FDA approval and Medicare coverage, reaches under 1% of an estimated 2 million eligible Alzheimer's patients, constrained by a 20-month GP-to-infusion referral funnel and diagnostic infrastructure gaps. Building payer strategy, outcomes-based access models, and patient identification infrastructure in advance of launch is not optional -- it is the mechanism that converts label strength into real-world uptake.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call Kieu My Tucker at (919) 767-9223 if you have any questions.